IPO pricing is expected within 1-2 days. The $75.0M Regeneron anchor investment signals strong institutional backing. Monitor pricing announcement and first-day trading for liquidity and valuation read-through.
Price Chart
Executive Summary
Parabilis Medicines' S-1 registration statement (File No. 333-296032) became effective on June 9, 2026, clearing the way for the company's IPO of 33,333,334 shares at a $17.00-$19.00 price range. The offering includes a concurrent $75.0M private placement by Regeneron at 90% of the IPO price, and proceeds will fund clinical development of lead candidate zolucatetide in desmoid tumors, advance the preclinical pipeline, and extend cash runway into H2 2029.
Key Facts
- IPO registration declared effective on June 9, 2026
- Offering of 33,333,334 shares at $17.00-$19.00 per share
- Regeneron to invest $75.0M in private placement at 90% of IPO price
- Proceeds to fund zolucatetide clinical development and preclinical pipeline
- Cash runway extended into H2 2029
Financial Impact
Up to $633.3M gross IPO proceeds (33,333,334 shares × $19.00 midpoint) plus $75.0M Regeneron private placement, totaling up to ~$708.3M in new capital
Risk Factors
- Clinical-stage biotech with no approved products; zolucatetide development risk
- Dilution from 33.3M new shares; post-IPO share count will increase significantly
- Market conditions could impact IPO pricing and aftermarket performance
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001929 |
| Document: 9999999995-26-001929-index.html | 9999999995-26-001929 |
| Document: 9999999995-26-001929.txt | 9999999995-26-001929 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 2d ago | Press Release | $24.79 | awaiting T+60 | — | $25.03 (+0.97%) |
Oct 19, 2026 7d ago | Press Release | $25.35 | awaiting T+60 | — | $25.03 (−1.26%) |
Sep 15, 2026 5w ago | 8-K | $36.88 | awaiting T+60 | — | $25.03 (−32.13%) |
Sep 2, 2026 7w ago | 8-K | $40.75 | awaiting T+60 | — | $25.03 (−38.58%) |
Aug 13, 2026 10w ago | 8-K | $35.67 | awaiting T+60 | — | $25.03 (−29.83%) |
Aug 13, 2026 10w ago | Press Release | $35.67 | awaiting T+60 | — | $25.03 (−29.83%) |
Jul 22, 2026 13w ago | Insider Buy | $32.81 $22.75 | ▼ −30.66% | ▼ −34.31% | $25.03 (−23.71%) |
Jun 29, 2026 17w ago | Insider Cluster | $29.19 $33.31 | ▲ +14.11% | ▲ +10.50% | $25.03 (−14.25%) |
Jun 16, 2026 18w ago | Insider Cluster | $26.03 $36.16 | ▲ +38.92% | ▲ +36.23% | $25.03 (−3.84%) |
Jun 15, 2026 18w ago | Insider Cluster | $26.59 $36.88 | ▲ +38.70% | ▲ +36.84% | $25.03 (−5.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers